Clinicopathological Characteristics and Prognosis of Signet Ring Gastric Cancer: A Population-Based Study

Qing Wei†, Yiding Gao†, Changsong Qi‡, Xing Yuan†, Jingjing Li†, Qi Xu†, Cong Luo†, Lei Chen†, Wei Zhuo‡, Zhiyuan Xu§ and Jieer Ying†

† Department of Abdominal Medical Oncology, Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China, 2 The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China, 3 Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, 4 Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou, China, 5 Department of Gastric Surgery, Institute of Cancer and Basic Medicine (ICBM), Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, China

Background: To better define the clinicopathologic characteristics of signet ring cell (SRC) gastric cancer and build a prognostic model for it.

Methods: SRC patient information from 2010 to 2015 were identified using Surveillance, Epidemiology, and End Results (SEER) database. Kaplan-Meier method and log-rank test were used to estimate Overall survival (OS) and to determine associations with histologic subtypes. In COX proportional hazards regression model–based univariate and multivariate analyses, significant variables for construction of a nomogram were screened out. The nomogram was validated by means of the concordance index (CI), calibration plots, and receiver operating characteristics (ROCs) curves.

Results: A total of 11,363 gastric cancer patients were enrolled. On dividing the patients into SRC, well-to-moderately differentiated (WMD) adenocarcinoma, and poorly differentiated (PD) adenocarcinoma, differences among these subgroups emerged. SRC patients were more likely to occur in female and young patients than other histologic subtypes. Larger tumors, stage T4, and node stage N3 were more likely to be found in the SRC group. The survival for SRC patients was better than non-SRC patients in stage I. Univariate and multivariate analyses identified age, tumor site, larger tumor size, advanced T classification, advanced N classification, advanced TNM stage, and surgery of primary site as independent prognostic indicators. Then an OS nomogram was formulated.

Conclusions: SRC had distinct clinicopathological characteristics. The nomogram provided an accurate tool to evaluate the prognosis of SRC.

Keywords: carcinoma, signet ring cell, nomograms, stomach neoplasms, prognosis
BACKGROUND

Based on GLOBOCAN 2012, gastric cancer (GC) is the fifth most frequently diagnosed malignancy (1) and the third leading cause of cancer death worldwide (2). It is a heterogeneous disease with different architectural, cytologic, and molecular alterations (3). Signet ring cell carcinoma (SRC) is a variant of adenocarcinoma (AC) and defined by the presence of >50% of tumor cells with large mucin vacuole, which abundantly fills the cytoplasm, resulting in compression and eccentric displacement of the nucleus (4). Specific signatures found on gastric SRC carcinoma distinguish them from non-SRC subtype. SRC is weakly cohesive and prone to grow invasively, and early carcinoma distinguish them from non-SRC subtype. SRC is nucleus (4). Specific signatures found on gastric SRC carcinoma distinguish them from non-SRC subtype. SRC is weakly cohesive and prone to grow invasively, and early studies confirm that SRC portends poor prognosis (5). However, some comparative studies have reported that the prognosis of SRC were conflicting and appeared to depend on tumor stage (6-8). These different findings can be explained by the ethnicity, heterogeneity, and different entry criteria in study design. Unlike the decline in the incidence of GC, research reveals that the incidence of SRC carcinoma subtype continues to rise (8-10). This phenomenon prompts us to re-evaluate this subtype. A large volume of patients and a comparison with non-SRC subtypes are necessary for a prognostic analysis.

Through the application of the Surveillance, Epidemiology, and End Results (SEER) database, sufficient cases were provided for the establishment of a nomogram for SRC. Nomogram-based clinical modeling with visual and mathematical advantages has been currently widely used in clinical research. Its establishment facilitates clinical prognosis assessment and probability calculation of risk factors (11). In fact, given the unclear prognosis of SRC, this study analyzed risk factors for this disease through this statistically enhanced clinical model.

Hence, the aim of this study is to analyze the clinicopathological features of SRC and prognostic factors of SRC and to contrive a new prognostic model.

PATIENTS AND METHODS

Data Source
Clinicopathological data and prognostic outcomes of GC patients diagnosed and treated between 2010 and 2015 were exported from SEER*Stat 8.3.5 software to Microsoft Excel for further analysis. The identification of GC was based on the Site record ICD-0-3/WHO 2008. The inclusion criteria were: (I) a single primary tumor; (II) known race; (III) known grade and histology; (IV) known tumor size and surgical resection (yes or no); (V) known tumor site; (VI) complete tumor-node-metastasis (TNM) stage information; (VII) complete follow-up data. Due to SEER data is publicly available, approval was waived by the local ethics committee.

Study Sample
Clinical variables included sex, age, grade, race, histology, tumor site, tumor size, American Joint Committee on Cancer (AJCC) TNM stage, surgical resection (yes or no), vital status, and survival data.

Statistical Analysis
X-tile software version 3.6.1 (Yale University School of Medicine, USA) was used to select optimal tumor size and age cut-points. Group comparisons were performed with the use of Fisher’s exact test or chi-square tests for categorical variables. Overall survival (OS) was the interval from the date of diagnosis until the date of death from any cause or the date of the last follow-up. Survival curves were generated using the Kaplan-Meier (KM) method. Significant variables were screened out by Cox proportional hazards regression analysis, and variables with P values < 0.05 in univariate analysis (UVA) were further used for multivariate analysis (MVA) and nomogram construction. To evaluate discrimination between performance and predicted results, we calculated concordance index (C-index). Larger values of the c-index indicate a better ability of the model to discriminate subjects with events from those without events (12-14). Calibration plots were carried out to evaluate the predictive performance of the prognostic nomogram (15). The predictive accuracy, sensitivity, and specificity values of the nomogram were determined via receiver operating characteristic (ROCs) curves. R version 3.4.0 software (R Foundation for Statistical Computing, Vienna, Austria) (http://www.r-project.org/) and SPSS 23.0 software (IBM Corporation, Chicago, IL, USA) were used for statistical analysis. Statistical tests were two-sided, and P values of less than 0.05 were considered to indicate statistical significance.

RESULTS

Patient Demographics
A total of 11,363 patients were enrolled from the SEER database, including 1,751 patients (15.4%) with SRC (Figure 1). As depicted in Table 1, 3,231 (28.4%) were well-to-moderately differentiated (WMD), and 4,262 (37.5%) were poorly differentiated (PD). Compared with patients in WMD or PD, the age at initial diagnosis of SRC patients was younger. About 12.4% of SRC patients, 6.5% of PD, and only 3.1% of WMD patients were younger than 45 years (P < 0.001).

The peak age range of both the WMD and PD groups was 60–64 years old, whereas SRC group was 55–59 years old, with a younger age distribution. In terms of gender, the proportion of females was higher in SRC (SRC: 47.2%; WMD: 29.9%; PD: 33.6%; P < 0.001).

Tumor Presentation
Most cases of SRC (94.9%) were classified as Grade III. Tumor location distribution is listed in Table 2. SRC occurs at a higher proportion in the middle stomach, defined as the body (SRC: 13.0%; WMD: 8.0%; PD: 10.5%), greater curvature (SRC: 6.2%; WMD: 3.3%; PD: 4.5%), and lesser curvature (SRC: 13.7%; WMD: 8.8%; PD: 11.5%), and the lower stomach, defined as the antrum (SRC: 27.5%; WMD: 24.4%; PD: 23.5%) or pylorus (SRC: 4.6%; WMD: 2.9%; PD: 3.5%). WMD and PD were more common in the upper stomach, defined as the cardia (SRC: 4.6%; WMD: 2.9%; PD: 3.5%) or fundus (SRC: 3.2%; WMD: 3.6%);
Patients diagnosed with gastric cancer from 2010 to 2015

Removal of patients with multiple primary tumors

Removal of patients with unknown race

Removal of patients with unknown AJCC staging

Removal of patients with unknown primary tumor site

Removal of patients with unknown histological classification, tumor size and pathological grade classification

Removal of patients with unknown surgery status and vital status

**FIGURE 1** | CONSORT diagram. AJCC, American Joint Committee on Cancer, 7th edition.

**TABLE 1** | Demographic characteristics of study subjects.

| Variable | Signet Ring Cell Carcinoma (A) (N = 1,751) | Well and Moderately Differentiated AC (B) (N = 3,231) | P (AvsB) | Poorly Differentiated AC(C) (N = 4,262) | P (AvsC) |
|----------|------------------------------------------|------------------------------------------------|----------|---------------------------------------|----------|
| SEX      |                                          |                                                |          |                                       |          |
| Male     | 925                                      | 2,266                                         | <0.001   | 2,828                                 | 66.4%    | <0.001|
| Female   | 826                                      | 965                                           | 70.1%    | 1434                                  | 33.8%    |        |
| Age, years |                                          |                                                |          |                                       |          |
| <45      | 217                                      | 100                                           | <0.001   | 276                                   | 6.5%     | <0.001|
| >=45     | 1,537                                    | 3,131                                         | 96.9%    | 3,086                                 | 93.5%    |        |
| Race     |                                          |                                                |          |                                       |          |
| White    | 1,153                                    | 2,231                                         | 69.0%    | 2,888                                 | 67.8%    | 0.133  |
| Black    | 214                                      | 429                                           | 13.3%    | 537                                   | 12.6%    |        |
| Other    | 384                                      | 571                                           | 17.7%    | 837                                   | 19.6%    |        |

AC, adenocarcinoma.

PD: 3.1%). Overlapping locations were seen the most in the SRC (SRC: 12.2%; WMD: 5.0%; PD: 8.5%). In terms of tumor size, SRC (96.4%) had larger tumor size than WMD, whereas PD presented as the largest tumor. At initial diagnosis, compared with other two types of patients, SRC had a higher proportion presented with tumor stage T4 (SRC: 33.4%; WMD: 12.7%; PD: 26.9%). More patients with SRC presented with node stage N3 (SRC: 25.5%; WMD: 12.7%; PD: 26.9%). In terms of TNM staging, the proportion of SRC, WMD, and PD patients at stage I was 20.8, 38.4, and 15.2%. Patients with SRC were seen more frequently at stage IV, though a higher proportion of patients with stage IV were in the PD group (SRC: 20.0%; WMD: 14.7%; PD: 22.5%).

Metastasis sites for different subtypes of gastric cancer are presented in Table 3. In our study, we found that patients with SRC have a higher risk of bone metastasis than those with WMD.
and PD (SRC: 13.90%; WMD: 6.70%; PD: 11.60%). However, WMD and PD subtypes had significantly higher rate of liver (SRC: 13.20%; WMD: 59.10%; PD: 41.60%) and lung metastasis (SRC: 10.80%; WMD: 17.00%; PD: 14.40%). Brain metastasis from GC is relatively rare, and the incidence rate is low in every subtype (SRC: 1.20%; WMD: 2.30%; PD: 1.00%).

### TABLE 2 | Tumor characteristics at presentation.

| Variable                  | Signet Ring Cell Carcinoma (A) (N = 1,751) | Well and Moderately Differentiated AC (B) (N = 3,231) | P (AvsB) | Poorly Differentiated AC (C) (N = 4,262) | P (AvsC) |
|---------------------------|--------------------------------------------|------------------------------------------------------|----------|------------------------------------------|----------|
|                           | N  | %               | N  | %               | N  | %               |          |          |          |
| Grade                     |    |                 |    |                 |    |                 |          |          |          |
| I                         | 2  | 0.1%            | 501| 15.5%           | NA | 0                | NA       |          |          |
| II                        | 42 | 2.4%            | 2,730| 84.5%          | 0  | 0                |          |          |          |
| III                       | 1,661| 94.9%         | 0  | 0               | 4,262| 100.0%         |          |          |          |
| IV                        | 46 | 2.6%            | 0  | 0               | 0  | 0                |          |          |          |
| Tumor site                |    |                 |    |                 |    |                 |          |          |          |
| Cardia, NOS               | 343| 19.6%           | 1,379| 44.0%         | <0.001| 1,487| 34.9%         | <0.001   |
| Fundus of stomach         | 56 | 3.2%            | 113 | 3.6%           | 132 | 3.1%            |          |          |          |
| Body of stomach           | 227| 13.0%           | 250 | 8.0%           | 448 | 10.5%           |          |          |          |
| Gastric antrum            | 462| 27.5%           | 764 | 24.4%          | 1,003| 23.5%           |          |          |          |
| Pylorus                   | 81 | 4.6%            | 91  | 2.9%           | 148 | 3.5%            |          |          |          |
| Lesser curvature of stomach, NOS | 240| 13.7%         | 274 | 8.8%           | 491 | 11.5%           |          |          |          |
| Greater curvature of stomach, NOS | 108| 6.2%          | 103 | 3.3%           | 191 | 4.5%            |          |          |          |
| Overlapping lesion of stomach | 214| 12.2%         | 157 | 5.0%           | 362 | 8.5%            |          |          |          |
| Tumor size                |    |                 |    |                 |    |                 |          |          |          |
| <25 mm                    | 418| 23.9%           | 976 | 31.2%          | <0.001| 764 | 17.9%         | <0.001   |
| 25–46 mm                  | 553| 31.6%           | 1,064| 34.0%         | 1,489| 34.9%           |          |          |          |
| >46 mm                    | 780| 44.5%           | 1,091| 34.8%         | 2,009| 47.1%           |          |          |          |
| AJCC T stage (7th)        |    |                 |    |                 |    |                 |          |          |          |
| T1                        | 380| 21.7%           | 1,182| 37.8%         | <0.001| 874 | 20.5%         | <0.001   |
| T2                        | 187| 10.7%           | 436 | 13.9%          | 485 | 11.4%           |          |          |          |
| T3                        | 600| 34.3%           | 1,114| 36.6%         | 1,757| 41.2%           |          |          |          |
| T4                        | 584| 33.4%           | 399 | 12.7%          | 1,146| 26.9%           |          |          |          |
| AJCC N stage (7th)        |    |                 |    |                 |    |                 |          |          |          |
| N0                        | 646| 36.9%           | 1,695| 54.1%         | <0.001| 1,416| 33.2%         | <0.001   |
| N1                        | 394| 22.5%           | 832 | 26.6%          | 1,326| 31.1%           |          |          |          |
| N2                        | 264| 15.1%           | 359 | 11.5%          | 718 | 16.8%           |          |          |          |
| N3                        | 447| 25.5%           | 245 | 7.8%           | 802 | 18.8%           |          |          |          |
| AJCC TNM stage (7th)      |    |                 |    |                 |    |                 |          |          |          |
| I                         | 364| 20.8%           | 1,201| 38.4%         | <0.001| 648 | 15.2%         | <0.001   |
| II                        | 352| 20.1%           | 662 | 21.1%          | 986 | 23.1%           |          |          |          |
| III                       | 894| 39.1%           | 807 | 25.8%          | 1,668| 39.1%           |          |          |          |
| IV                        | 351| 20.0%           | 461 | 14.7%          | 960 | 22.5%           |          |          |          |

AJCC, American Joint Committee on Cancer, 7th edition; NOS, Not Otherwise Specified; NA, not applicable.

### TABLE 3 | Metastasis sites for different subtypes of gastric cancer.

| Variable                  | Signet Ring Cell Carcinoma (A) (N = 567) | Well and Moderately Differentiated AC (B) (N = 599) | P (AvsB) | Poorly Differentiated AC (C) (N = 1,412) | P (AvsC) |
|---------------------------|--------------------------------------------|------------------------------------------------------|----------|------------------------------------------|----------|
|                           | N  | %               | N  | %               | N  | %               |          |          |          |
| Bone metastases           |    |                 |    |                 |    |                 |          |          |          |
| Yes                       | 79 | 13.90%          | 40 | 6.70%           | <0.001| 164 | 11.60%         | 0.155    |
| No                        | 488| 86.10%          | 559| 93.30%          | 1,248| 88.40%           |          |          |          |
| Liver metastases          |    |                 |    |                 |    |                 |          |          |          |
| Yes                       | 75 | 13.20%          | 354| 59.10%          | <0.001| 588 | 41.60%         | <0.001   |
| No                        | 492| 86.80%          | 245| 40.90%          | 824 | 58.40%           |          |          |          |
| Brain metastases          |    |                 |    |                 |    |                 |          |          |          |
| Yes                       | 7  | 1.20%           | 14 | 2.30%           | 0.157| 14  | 1.00%         | 0.633    |
| No                        | 560| 98.80%          | 585| 97.70%          | 1,398| 99.00%           |          |          |          |
| Lung metastases           |    |                 |    |                 |    |                 |          |          |          |
| Yes                       | 61 | 10.80%          | 102| 17.00%          | 0.002| 204 | 14.40%         | 0.029    |
| No                        | 506| 89.20%          | 497| 83.00%          | 1,208| 85.60%           |          |          |          |

AC, adenocarcinoma.
Survival
KM curves were calculated based on pathologic classification and are shown in Figure 2. The median OS are as follows: SRC: 21 months; WMD: 37 months; PD: 19 months; P < 0.001 (Figure 2A). Intriguingly, regarding individual stages, for patients presented with stage I, SRC patients have longer survival (SRC: 65 months; WMD: 59 months; PD: 56 months; P < 0.001; Figure 2B). There was no statistical difference among the three groups in stage II (SRC: 39 months; WMD: 44 months; PD: 42 months; P = 0.255; Figure 2C). In stage III, compared with SRC and PD patients, the best survival was observed in WMD (SRC: 18 months; WMD: 25 months; PD: 18 months; P < 0.001; Figure 2D). When comparing stage IV cancers, survival was not significantly different (SRC: 9 months; WMD: 8 months; PD: 7 months; P = 0.105; Figure 2E).

Predictors of Mortality
As univariate analysis showed, older age, race, larger tumor size, tumor site, surgery of primary site, advanced T or N classification, and TNM staging system (all P < 0.001) were
significantly identified in univariate analysis (Table 4). In multivariate analysis for OS, older age (P = 0.001; HR = 1.414; 95% CI: 1.152–1.736), tumor site (P = 0.002), larger tumor size (P < 0.001), advanced T classification (P < 0.001), advanced N classification (P = 0.001), advanced TNM stage (P < 0.001), and surgery of primary site (P < 0.001) were identified as independent prognostic indicators. Next, an OS nomogram was developed based on these risk factors (Figure 3).

**Nomogram Validation**

The C-index for OS prediction with the formulated nomogram was 0.751 (95% CI: 0.735–0.767). This high C-index predicts the excellent accuracy of the system. Three- and 5-year OS showed consistency with the OS nomogram, as shown in the calibration plot (Figure 4). Additionally, a large area under the ROC curve (AUC) was noted for both 3- and 5-year OS curves (Figure 5).

**DISCUSSION**

We reaffirmed that SRC has features distinct from those of gastric adenocarcinoma. Age, T stage, N stage, TNM stage, surgery, tumor size, and tumor site can be treated as independent prognostic factors related to survival, and a nomogram was

| Variable | Univariate analysis | Multivariate analysis |
|----------|---------------------|----------------------|
| SEX      |                     |                      |
| Female   | reference           |                      |
| Male     | 1.070 (0.940–1.218) | 0.28                 |
| Age, years |                   | <0.001               |
| <45      | reference           | 1.395 (1.141–1.705)  |
| >=45     |                     | 0.001                |
| Race     |                     |                      |
| White    | reference           |                      |
| Black    | 1.058 (0.882–1.270) | 0.068                |
| Other    | 0.707 (0.603–0.830) | 0.832 (0.706–0.979)  |
| Grade    |                     |                      |
| I–II     |                     | 0.177                |
| III–IV   | 1.112 (0.919–1.305) | 0.002                |
| Tumor site |                   |                      |
| Cardia, NOS | reference            |                      |
| Fundus of stomach | 0.763 (0.525–1.089) | 0.914 (1.094–1.316) |
| Body of stomach | 0.700 (0.581–0.873) | 1.031 (0.970–1.300) |
| Gastric antrum | 0.726 (0.608–0.867) | 1.209 (0.827–1.477) |
| Pylorus | 0.702 (0.509–0.970) | 1.154 (0.867–1.623) |
| Lesser curvature of stomach, NOS | 0.646 (0.518–0.804) | 1.021 (0.980–1.291) |
| Greater curvature of stomach, NOS | 0.702 (0.524–0.940) | 1.167 (0.857–1.584) |
| Overlapping lesion of stomach | 1.297 (1.062–1.584) | 1.381 (0.724–1.719) |
| Tumor size |                   |                      |
| <25 mm  | reference           |                      |
| 25–46 mm | 1.701 (1.402–2.064) | 1.166 (0.858–1.430) |
| >46 mm  | 2.820 (2.361–3.369) | 1.384 (0.723–1.690) |
| AJCC T stage (7th) |             |                      |
| T1      | reference           |                      |
| T2      | 1.095 (0.823–1.456) | 0.7193 (0.526–0.983) |
| T3      | 2.150 (1.763–2.622) | 0.8483 (0.649–1.110) |
| T4      | 3.553 (2.924–3.137) | 1.2474 (0.947–1.643) |
| AJCC N stage (7th) |             |                      |
| N0      | reference           |                      |
| N1      | 1.887 (1.422–2.002) | 0.940 (0.775–1.140) |
| N2      | 1.550 (1.280–1.877) | 0.874 (0.689–1.109) |
| N3      | 2.340 (1.996–2.742) | 1.335 (1.059–1.682) |
| AJCC TNM stage (7th) |             |                      |
| I       | reference           |                      |
| II      | 2.375 (1.824–3.092) | 2.225 (1.587–3.118) |
| III     | 4.480 (3.549–5.655) | 3.459 (2.359–5.043) |
| IV      | 9.919 (7.755–12.687) | 4.843 (3.386–6.926) |
| Surgery at primary site |             |                      |
| Not performed | reference     |                      |
| Performed | 0.280 (0.245–0.320) | 0.282 (0.236–0.336) |

AJCC, American Joint Committee on Cancer, 7th edition; CI, Confidence Interval.
established to predict the prognosis. By solid validation, the nomogram displayed outcomes with high accuracy.

SRC is more frequent in younger patients, especially female patients, which is similar to the research result observed by the Asian Cancer Center (7). The epidemiology showed consistency between eastern and western countries. SRC also differs in the clinical features from adenocarcinoma and appears more frequently in the middle or lower stomach; the results are the same as those of Theuer et al. (16).

From 2010 on, SEER database started to release metastatic pattern including liver, lung, bone, and brain. Our research found that SRC was more likely to have bone metastasis, while
WMD and PD were more prone to have lung and liver metastases. It is suggested that clinicians take the pathological subtypes into account when designing pretreatment imaging evaluation for GC patients (17).

SRC is associated with more advanced stages, with more patients appearing at AJCC stage IV, with more advanced T and N stages and higher tumor grade. The result of this research is similar to a previous study that reported that SRC patients were more common in the late stages (8). However, in Hong’s study, 60% of SRC patients were early gastric cancer at diagnosis (7). Thus, we thought that stage adjustments are crucial to illustrate the prognosis of SRC.

Interestingly, the prognosis of advanced-stage SRC is controversial (18). A large-volume study based on SEER found patients with stage IV SRC had better survival. Conversely, several Asian studies have reported poor prognosis in later stages of the disease (19, 20). The primary finding of our research is that compared with adenocarcinoma, when performing stratified analysis by the AJCC stage, SRC is not independently associated with mortality. Furthermore, an improved survival with stage I SRC compared with adenocarcinoma was detected. A study in South Korea reported a lower rate of lymph node (LN) metastasis in early-stage gastric SRC (21). SRC is not more aggressive than differentiated cancer in all stages (22). The transition of prognosis as the disease progressed might indicate that underlying mutations controlling the pernicious potential of SRC happen late in the disease course. Deep understanding of the molecular changes associated with SRC is urgently needed.

This research constructed and validated an OS nomogram prognostic model, which can facilitate individualized treatment and prognostic assessment. In multivariate analysis, the optimal-cutoff categorized tumor size has been deemed to be a significant independent element of prognosis. As a result, the concept of tumor size was involved in the formulated nomogram. Actually, conventional categorization by sizes of 5 and 10 cm did not fully reflect the prognostic value of tumor size in SRC (23). According to our finding, compared with tumor size <25 mm, tumor size between 25 and 46 mm has a significantly higher risk. Moreover, tumor size >46 mm showed the highest risk.

In a previous study, Saito et al. had observed that large-size tumor was an independent prognostic factor with worse prognosis (24). Large size stimulates angiogenesis, which increases tumor cell proliferation. The underlying mechanism remains to be studied.

Meanwhile, there remain some limitations to our study. First, since the classification of GC subtypes may be different, we compared only those cases with clear pathological types. Another limitation of this study is the retrospective essence, which may result in recall bias. A prospective research is warranted in the future. Next, because this study only included the Western population, it could not represent universal situation of gastric cancer. Therefore, further global studies of SRC gastric cancer are needed to verify the current study.
DATA AVAILABILITY STATEMENT
Publicly available datasets were analyzed in this study. This data can be found here: Surveillance, Epidemiology, and End Results (SEER) database (https://seer.cancer.gov/).

AUTHOR CONTRIBUTIONS
QW collected and analyzed data. QW, YDG and CSQ wrote the manuscript. XY, JLL, QX, CL, LC, WZ revised the manuscript. XY participated in statistical analysis. ZYX and JY developed study conception and design, provided supervision for the study, and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This project was funded by Zhejiang Provincial Natural Science Fund (No.LQ21H160005).

ACKNOWLEDGMENTS
We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

REFERENCES
1. Fleray J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. Int J Cancer (2015) 136:E359–86. doi: 10.1002/ijc.29210
2. Zhang XY, Zhang PY. Gastric Cancer: Somatic Genetics as a Guide to Therapy. J Med Genet (2017) 54:305–12. doi: 10.1136/jmedgenet-2016-104171
3. Gigek CO, Calcagno DQ, Rasmussen LT, Santos LC, Leal MF, Wnieski MF, et al. Genetic Variants in Gastric Cancer: Risks and Clinical Implications. Exp Mol Pathol (2017) 103:101–11. doi: 10.1016/j.yexmp.2017.07.004
4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. Geneva: World Health Organization (2010)
5. Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C. Signet Ring Cell Histology Is an Independent Predictor of Poor Prognosis in Gastric Adenocarcinoma Regardless of Tumoral Clinical Presentation. Ann Surg (2009) 250:878–87. doi: 10.1097/SLA.0b013e3181b21c7b
6. Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, et al. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-Volume Center in Asia. Ann Surg Oncol (2017) 265:496–53. doi: 10.1007/s10434-00000000001793
7. Taghavi S, Jayarajan SN, Davey A, Willis AJ. Prognostic Significance of Signet Ring Gastric Cancer. J Clin Oncol (2012) 30:3493–8. doi: 1200/JCO.2012.42.6635
8. Bamboat ZM, Tang LH, Vinuela E, Kuk D, Gonen M, Shah MA, et al. Stage-Stratified Prognosis of Signet Ring Cell Histology in Patients Undergoing Curative Resection for Gastric Adenocarcinoma. Ann Surg Oncol (2014) 21:1678–85. doi: 10.1245/s10434-013-3466-8
9. Peng J, Xiao P, Liao B, Ye J, He Y. Analysis of Clinicopathological Features of 1879 Cases of Gastric Cancer in Southern China: A Single Center Experience. Zhonghua Wai Ke Za Zhi (2014) 52:168–70. doi: 10.3760/cma.j.issn.0529-5815.2014.03.003
10. Henson DE, Dittus C, Younes M, Nguyen H, Alboreos-Savedra J. Differential Trends in the Intestinal and Diffuse Types of Gastric Carcinoma in the United States, 1973-2000: Increase in the Signet Ring Cell Type. Arch Pathol Lab Med (2004) 128:765–70. doi: 10.5858/2004-128-765-DTTTA
11. Gold JS, Gonen M, Gutierrez A, Broto JM, Garcia-del-Muro X, Smyrk TC, et al. Development and Validation of a Prognostic Nomogram for Recurrence-Free Survival After Complete Surgical Resection of Localised Primary Gastrointestinal Stromal Tumour: A Retrospective Analysis. Lancet Oncol (2009) 10:1045–52. doi: 10.1016/s1470-2245(09)70242-6
12. Yin J, Yang Y, Ma K, Yang X, Lu T, Wang S, et al. Clinicopathological Characteristics and Prognosis of Pulmonary Plasmocytic Carcinoma: A Population-Based Retrospective Study Using SEER Data. J Thorac Dis (2018) 10:4262–73. doi: 10.21037/jtd.2018.06.07
13. Koepsell TD, Weiss NS. Epidemiologic Methods: Studying the Occurrence of Illness. Oxford, UK: Oxford University Press (2014).
14. Ma K, Sun F, Yang X, Wang S, Wang L, Jin Y, et al. Prognosis of Patients With Primary Malignant Main Stem Bronchial Tumors: 7,418 Cases Based on the SEER Database. Onco Targets Ther (2018) 11:83–95. doi: 10.2147/OTT.S142847
15. Wang S, Ma K, Wang Q, Sun F, Shi Y, Zhan C, et al. The Revised Staging System for Malignant Pleural Mesothelioma Based on Surveillance, Epidemiology, and End Results Database. Int J Surg (2017) 49:92–8. doi: 10.1016/j.ijsu.2017.10.034
16. Theuer CP, Nastanski F, Brewster WR, Butler JA, Anton-Culver H. Signet Ring Cell Histology Is Associated With Unique Clinical Features But Does Not Affect Gastric Cancer Survival. Am J Cancer (1999) 65:915–21.
17. Qiu M, Shi S, Chen Z, Yu HE, Sheng H, Jin Y, et al. Frequency and Clinicopathological Features of Metastasis to Liver, Lung, Bone, and Brain From Gastric Cancer: A SEER-Based Study. Cancer Med (2017) 8:7662–72. doi: 10.1002/cam4.1661
18. Machlowska J, Puculek M, Sitarz M, Terlecki P, Maciejewski P, Sitarz R. Stage of the Art for Gastric Signet Ring Cell Carcinoma: From Classification, Prognosis, and Genomic Characteristics to Specified Treatments. Cancer Manag Res (2019) 11:2151–61. doi: 10.2147/CMAR.S188622
19. Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, et al. Advanced Gastric Carcinoma With Signet Ring Cell Histology. Oncology (2007) 72:64–8. doi: 10.1159/000111096
20. Otsuji E, Yamaguchi T, Sawai K, Takahashi T. Characterization of Signet Ring Cell Carcinoma of the Stomach. J Surg Oncol (1999) 67:226–20. doi: 10.1002/(SICI)1096-9098(199804)67:4–216:AID-IS0-3.0.CO;2-B
21. Hyung WJ, Noh SH, Lee JH, Huh JJ, Lah KH, Choi SH, et al. Early Gastric Carcinoma With Signet Ring Cell Histology. Cancer (2002) 94:78–83. doi: 10.1002/cncr.10120
22. Kang SH, Kim JS, Moon HS, Lee ES, Kim SH, Sung JK, et al. Signet Ring Cell Carcinoma of Early Gastric Cancer, Is Endoscopic Treatment Really Risky? Medicine (2017) 96(33):e7532. doi: 10.1097/MD.0000000000007532
23. Yu C, Zhang Y. Development and Validation of Prognostic Nomogram for Young Patients With Gastric Cancer. Ann Transl Med (2019) 7:641. doi: 10.21037/atm.2019.10.77
24. Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Oro S, et al. Macroscopic Tumor Size as a Simple Prognostic Indicator in Patients With Gastric Cancer. Am J Surg (2006) 192:296–300. doi: 10.1016/j.amjsurg.2006.03.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wei, Gao, Qi, Yuan, Li, Xu, Luo, Chen, Zhao, Xu and Ying. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.